2025 Q4 -tulosraportti
44 päivää sitten
‧49 min
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 2 000 | - | - | ||
| 113 | - | - | ||
| 25 | - | - | ||
| 111 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 766 113 | 3 766 113 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 766 113 | 3 766 113 | 0 | 0 |
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·10 t sitten · MuokattuAsked AI further (Gemini AI) : So AACR could lead to further maturation of partner talks? The AACR Annual Meeting (starting next week, April 17–22) is the industry's largest "speed dating" event for oncology biotech. While Borcherding has been characteristically tight-lipped about specific names, the shift in his recent rhetoric suggests that partnership maturation is a primary goal for this spring. Here is how the next two weeks could turn the "news drought" into a "deal flow" environment: 🤔 Obs! Note "can"! "1. The Shift to "Strategic Account Managers" In the late-February Q4 call, Borcherding revealed a pivot: the company has finally hired three Strategic Account Managers to take over from the management team. The Maturity Link: Bringing in dedicated sales leadership suggests the product is now "packaged" and ready for a larger partner's infrastructure. Big diagnostic players (like Quest or Labcorp) rarely look at a company that is still "founder-selling." Now that Immunovia has a standardized sales funnel and a national footprint (47 states), they look like a plug-and-play asset." "2. The San Diego "Backroom" Talks The AACR isn't just about posters; it’s about the Oncology Industry Partnering Event (running concurrently). Immunovia’s "Lean Model" strategy—which they’ve touted since late 2025—is designed specifically to make them an attractive acquisition or licensing target. By licensing the IP back from Proteomedix in early 2026, Immunovia now "owns its destiny." This was a major barrier to partnership before; no big player wants to negotiate with a middleman. Now that Immunovia owns the full stack of PancreaSure reagents, a deal can be signed on a single sheet of paper." "3. "Validation" for Big Pharma At AACR, the "customers" are often pharma companies (like AstraZeneca or Merck) who need better ways to find Stage 1 patients for their drug trials. PancreaSure’s specificity of 94% is exactly what trial sponsors want to avoid "false positives" that ruin study data. Expect "maturation" in the form of Research Collaboration Agreements. Even if it isn't a full buyout, a partnership where a major pharma company uses PancreaSure to screen for their clinical trials would be a massive validator for the stock." "4. The "New York" Domino If Borcherding is "on time" with New York, that acceptance is likely the final "due diligence" checkbox for a partner. Why it matters: A national diagnostic partner cannot sign a deal if 20 million people in the New York market are legally excluded from the test. Clearing New York effectively "unlocks" the entire US population, removing the last legal risk for a potential acquirer." "Summary: What to watch for this/next week Institutional volume: Look for unusual buying patterns ahead of the April 17th AACR kickoff. The "Late-Breaking" Abstract: If Immunovia drops an abstract next week showing real-world results from their NYU Langone or Stanford surveillance sites, it’s a signal that clinical adoption is moving faster than the market realizes. The "maturation" is happening because the company has moved from "proving the science" to "proving the business." Borcherding's confidence implies he isn't just waiting for New York; he's waiting for the ink to dry."
·3 t sittenInteresting reading this. Quiet before the storm?? 🤞·3 t sittenIt's allowed to have a little hope that something might happen at least. Hope that "he who waits for something good, waits not in vain" rewards us. But a lot of waiting. Of course, a little good cautious rise recently.- 10 t sitten10 t sittenSpurte AI: Is Immunovia participating at the AACR? "Yes, Immunovia is participating in the AACR (American Association for Cancer Research) Annual Meeting 2026, which takes place from April 17–22 in San Diego. While they are not listed as a massive booth exhibitor (which is typical for their current "lean" operational model), their presence is strategically focused on the scientific and clinical validation of PancreaSure." "Institutional "Tire Kicking": Analysts from major banks use this week to vet the science. If the feedback from independent oncologists at the AACR is positive regarding PancreaSure's ease of use and price point ($897), it often leads to updated "Buy" ratings or price target increases in the following weeks."
- ·10 t sitten · MuokattuIs AI correct here in its tentative conclusion, that preparations are being made for volume? Actually old news, but the conclusion, how solid is it? See AI assessment below the links. https://www.bio-technopark.ch/en/news-en/9720/#:~:text=In%20return%2C%20Immunovia%20will%20make,property%20from%202026%20to%202032. 🤔 https://www.inderes.dk/en/releases/immunovia-secures-control-of-pancreasuretm-supply-chain-and-achieves-cost-reduction-through-licensing-agreement "The Supply Chain "Clean-up" The quietness also stems from a significant "back-office" move in early 2026: Immunovia licensed the manufacturing IP from their partner Proteomedix. This gives them total control over the antibodies and reagents for PancreaSure. By owning the supply chain, they’ve cut reagent costs by 50%. This "housekeeping" is typical for a company preparing for a high-volume surge that usually follows a New York approval."
·1 päivä sittenOnly 140% left until Fair value :) (according to Carlsquare)·11 t sittenSome news from Immunovia would have helped. Waiting in anticipation. Things Take Time (TTT)- ·1 päivä sitten · MuokattuSo the base case is 0,41 öre according to Carlsquare? Bear 0,16 öre. https://forum.placera.se/inlagg/ebf878ad-124a-46ca-bd22-d9ce3a05f52e 🥳🤷🤦 https://carlsquare.com/wp-content/uploads/2026/02/Research-update-Immunovia-Q4-2025.pdf
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
44 päivää sitten
‧49 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·10 t sitten · MuokattuAsked AI further (Gemini AI) : So AACR could lead to further maturation of partner talks? The AACR Annual Meeting (starting next week, April 17–22) is the industry's largest "speed dating" event for oncology biotech. While Borcherding has been characteristically tight-lipped about specific names, the shift in his recent rhetoric suggests that partnership maturation is a primary goal for this spring. Here is how the next two weeks could turn the "news drought" into a "deal flow" environment: 🤔 Obs! Note "can"! "1. The Shift to "Strategic Account Managers" In the late-February Q4 call, Borcherding revealed a pivot: the company has finally hired three Strategic Account Managers to take over from the management team. The Maturity Link: Bringing in dedicated sales leadership suggests the product is now "packaged" and ready for a larger partner's infrastructure. Big diagnostic players (like Quest or Labcorp) rarely look at a company that is still "founder-selling." Now that Immunovia has a standardized sales funnel and a national footprint (47 states), they look like a plug-and-play asset." "2. The San Diego "Backroom" Talks The AACR isn't just about posters; it’s about the Oncology Industry Partnering Event (running concurrently). Immunovia’s "Lean Model" strategy—which they’ve touted since late 2025—is designed specifically to make them an attractive acquisition or licensing target. By licensing the IP back from Proteomedix in early 2026, Immunovia now "owns its destiny." This was a major barrier to partnership before; no big player wants to negotiate with a middleman. Now that Immunovia owns the full stack of PancreaSure reagents, a deal can be signed on a single sheet of paper." "3. "Validation" for Big Pharma At AACR, the "customers" are often pharma companies (like AstraZeneca or Merck) who need better ways to find Stage 1 patients for their drug trials. PancreaSure’s specificity of 94% is exactly what trial sponsors want to avoid "false positives" that ruin study data. Expect "maturation" in the form of Research Collaboration Agreements. Even if it isn't a full buyout, a partnership where a major pharma company uses PancreaSure to screen for their clinical trials would be a massive validator for the stock." "4. The "New York" Domino If Borcherding is "on time" with New York, that acceptance is likely the final "due diligence" checkbox for a partner. Why it matters: A national diagnostic partner cannot sign a deal if 20 million people in the New York market are legally excluded from the test. Clearing New York effectively "unlocks" the entire US population, removing the last legal risk for a potential acquirer." "Summary: What to watch for this/next week Institutional volume: Look for unusual buying patterns ahead of the April 17th AACR kickoff. The "Late-Breaking" Abstract: If Immunovia drops an abstract next week showing real-world results from their NYU Langone or Stanford surveillance sites, it’s a signal that clinical adoption is moving faster than the market realizes. The "maturation" is happening because the company has moved from "proving the science" to "proving the business." Borcherding's confidence implies he isn't just waiting for New York; he's waiting for the ink to dry."·3 t sittenInteresting reading this. Quiet before the storm?? 🤞·3 t sittenIt's allowed to have a little hope that something might happen at least. Hope that "he who waits for something good, waits not in vain" rewards us. But a lot of waiting. Of course, a little good cautious rise recently.
- 10 t sitten10 t sittenSpurte AI: Is Immunovia participating at the AACR? "Yes, Immunovia is participating in the AACR (American Association for Cancer Research) Annual Meeting 2026, which takes place from April 17–22 in San Diego. While they are not listed as a massive booth exhibitor (which is typical for their current "lean" operational model), their presence is strategically focused on the scientific and clinical validation of PancreaSure." "Institutional "Tire Kicking": Analysts from major banks use this week to vet the science. If the feedback from independent oncologists at the AACR is positive regarding PancreaSure's ease of use and price point ($897), it often leads to updated "Buy" ratings or price target increases in the following weeks."
- ·10 t sitten · MuokattuIs AI correct here in its tentative conclusion, that preparations are being made for volume? Actually old news, but the conclusion, how solid is it? See AI assessment below the links. https://www.bio-technopark.ch/en/news-en/9720/#:~:text=In%20return%2C%20Immunovia%20will%20make,property%20from%202026%20to%202032. 🤔 https://www.inderes.dk/en/releases/immunovia-secures-control-of-pancreasuretm-supply-chain-and-achieves-cost-reduction-through-licensing-agreement "The Supply Chain "Clean-up" The quietness also stems from a significant "back-office" move in early 2026: Immunovia licensed the manufacturing IP from their partner Proteomedix. This gives them total control over the antibodies and reagents for PancreaSure. By owning the supply chain, they’ve cut reagent costs by 50%. This "housekeeping" is typical for a company preparing for a high-volume surge that usually follows a New York approval."
- ·1 päivä sittenOnly 140% left until Fair value :) (according to Carlsquare)·11 t sittenSome news from Immunovia would have helped. Waiting in anticipation. Things Take Time (TTT)
- ·1 päivä sitten · MuokattuSo the base case is 0,41 öre according to Carlsquare? Bear 0,16 öre. https://forum.placera.se/inlagg/ebf878ad-124a-46ca-bd22-d9ce3a05f52e 🥳🤷🤦 https://carlsquare.com/wp-content/uploads/2026/02/Research-update-Immunovia-Q4-2025.pdf
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 2 000 | - | - | ||
| 113 | - | - | ||
| 25 | - | - | ||
| 111 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 766 113 | 3 766 113 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 766 113 | 3 766 113 | 0 | 0 |
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
2025 Q4 -tulosraportti
44 päivää sitten
‧49 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 24.2. | ||
2025 Q3 -tulosraportti 26.11.2025 | ||
2025 Q2 -tulosraportti 28.8.2025 | ||
2025 Q1 -tulosraportti 14.5.2025 | ||
2024 Q4 -tulosraportti 25.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·10 t sitten · MuokattuAsked AI further (Gemini AI) : So AACR could lead to further maturation of partner talks? The AACR Annual Meeting (starting next week, April 17–22) is the industry's largest "speed dating" event for oncology biotech. While Borcherding has been characteristically tight-lipped about specific names, the shift in his recent rhetoric suggests that partnership maturation is a primary goal for this spring. Here is how the next two weeks could turn the "news drought" into a "deal flow" environment: 🤔 Obs! Note "can"! "1. The Shift to "Strategic Account Managers" In the late-February Q4 call, Borcherding revealed a pivot: the company has finally hired three Strategic Account Managers to take over from the management team. The Maturity Link: Bringing in dedicated sales leadership suggests the product is now "packaged" and ready for a larger partner's infrastructure. Big diagnostic players (like Quest or Labcorp) rarely look at a company that is still "founder-selling." Now that Immunovia has a standardized sales funnel and a national footprint (47 states), they look like a plug-and-play asset." "2. The San Diego "Backroom" Talks The AACR isn't just about posters; it’s about the Oncology Industry Partnering Event (running concurrently). Immunovia’s "Lean Model" strategy—which they’ve touted since late 2025—is designed specifically to make them an attractive acquisition or licensing target. By licensing the IP back from Proteomedix in early 2026, Immunovia now "owns its destiny." This was a major barrier to partnership before; no big player wants to negotiate with a middleman. Now that Immunovia owns the full stack of PancreaSure reagents, a deal can be signed on a single sheet of paper." "3. "Validation" for Big Pharma At AACR, the "customers" are often pharma companies (like AstraZeneca or Merck) who need better ways to find Stage 1 patients for their drug trials. PancreaSure’s specificity of 94% is exactly what trial sponsors want to avoid "false positives" that ruin study data. Expect "maturation" in the form of Research Collaboration Agreements. Even if it isn't a full buyout, a partnership where a major pharma company uses PancreaSure to screen for their clinical trials would be a massive validator for the stock." "4. The "New York" Domino If Borcherding is "on time" with New York, that acceptance is likely the final "due diligence" checkbox for a partner. Why it matters: A national diagnostic partner cannot sign a deal if 20 million people in the New York market are legally excluded from the test. Clearing New York effectively "unlocks" the entire US population, removing the last legal risk for a potential acquirer." "Summary: What to watch for this/next week Institutional volume: Look for unusual buying patterns ahead of the April 17th AACR kickoff. The "Late-Breaking" Abstract: If Immunovia drops an abstract next week showing real-world results from their NYU Langone or Stanford surveillance sites, it’s a signal that clinical adoption is moving faster than the market realizes. The "maturation" is happening because the company has moved from "proving the science" to "proving the business." Borcherding's confidence implies he isn't just waiting for New York; he's waiting for the ink to dry."·3 t sittenInteresting reading this. Quiet before the storm?? 🤞·3 t sittenIt's allowed to have a little hope that something might happen at least. Hope that "he who waits for something good, waits not in vain" rewards us. But a lot of waiting. Of course, a little good cautious rise recently.
- 10 t sitten10 t sittenSpurte AI: Is Immunovia participating at the AACR? "Yes, Immunovia is participating in the AACR (American Association for Cancer Research) Annual Meeting 2026, which takes place from April 17–22 in San Diego. While they are not listed as a massive booth exhibitor (which is typical for their current "lean" operational model), their presence is strategically focused on the scientific and clinical validation of PancreaSure." "Institutional "Tire Kicking": Analysts from major banks use this week to vet the science. If the feedback from independent oncologists at the AACR is positive regarding PancreaSure's ease of use and price point ($897), it often leads to updated "Buy" ratings or price target increases in the following weeks."
- ·10 t sitten · MuokattuIs AI correct here in its tentative conclusion, that preparations are being made for volume? Actually old news, but the conclusion, how solid is it? See AI assessment below the links. https://www.bio-technopark.ch/en/news-en/9720/#:~:text=In%20return%2C%20Immunovia%20will%20make,property%20from%202026%20to%202032. 🤔 https://www.inderes.dk/en/releases/immunovia-secures-control-of-pancreasuretm-supply-chain-and-achieves-cost-reduction-through-licensing-agreement "The Supply Chain "Clean-up" The quietness also stems from a significant "back-office" move in early 2026: Immunovia licensed the manufacturing IP from their partner Proteomedix. This gives them total control over the antibodies and reagents for PancreaSure. By owning the supply chain, they’ve cut reagent costs by 50%. This "housekeeping" is typical for a company preparing for a high-volume surge that usually follows a New York approval."
- ·1 päivä sittenOnly 140% left until Fair value :) (according to Carlsquare)·11 t sittenSome news from Immunovia would have helped. Waiting in anticipation. Things Take Time (TTT)
- ·1 päivä sitten · MuokattuSo the base case is 0,41 öre according to Carlsquare? Bear 0,16 öre. https://forum.placera.se/inlagg/ebf878ad-124a-46ca-bd22-d9ce3a05f52e 🥳🤷🤦 https://carlsquare.com/wp-content/uploads/2026/02/Research-update-Immunovia-Q4-2025.pdf
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Stockholm
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 1 000 | - | - | ||
| 2 000 | - | - | ||
| 113 | - | - | ||
| 25 | - | - | ||
| 111 | - | - |
Välittäjätilasto
Ostaneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 766 113 | 3 766 113 | 0 | 0 |
Myyneet eniten
| Välittäjä | Ostettu | Myyty | Netto | Sisäinen |
|---|---|---|---|---|
| Anonyymi | 3 766 113 | 3 766 113 | 0 | 0 |